Drug Trial Radar · NCT07807969
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
605
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Annexon, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
Conditions
- Geographic Atrophy
Interventions
VonaprumentDrug
Form: solution for injection; Route of Administration: IVT injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse EventsTime frame: Through Month 24
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Retina Group of Florida
Sarasota, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Mid Atlantic Retina Specialists
Hagerstown, Maryland
Retina Research Institute at New England Retina Consultants
Springfield, Massachusetts
Asheville Eye Associates - Retina Division
Asheville, North Carolina
Verum Research, LLC
Eugene, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.